Gilead Sciences, Inc. (GILD) Stock Price & How to Invest

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the twice-yearly prevention injection Yeztugo (lenacapavir) for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care: HIV sales were about $5.7 billion in the second quarter of 2026, up 12% from a year earlier. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir (Veklury), now a shrinking contributor. Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer, and in 2026 it added Arcellx, Tubulis and Ouro Medicines, plus an October 2026 partnership with Vir Biotechnology on T-cell engagers for solid tumors. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generated about $30.5 billion of revenue over the last twelve months, pays a dividend of $3.28 per share a year, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. Hepatitis C revenue declined sharply after its cures shrank the patient pool, illustrating how success can erode markets, and Veklury sales are fading (2026 guidance cut to about $300 million). Its oncology expansion has been costly and uneven: the 2026 acquisitions pushed reported results to a GAAP loss of about $10.5 billion in the second quarter and a trailing net loss of about $3.2 billion, and the Immunomedics impairment shows acquired programs can underperform. Debt stood near $26 billion against about $4.9 billion of cash at the end of June. Drug development is risky, with frequent trial failures. The company faces regulatory, reimbursement, and drug-pricing policy pressures, including in the US. After a strong 2026 run the stock trades near the average analyst target of about $160, leaving less room for disappointment. Diversifying away from virology successfully is essential but unproven at scale.

26 analysts publish price targets on GILD, averaging $159.85 against a $156.19 price as of October 2026, or +2.3%. The published targets run from $126.00 to $180.00, a moderate spread, and the ratings split 22 buy, 5 hold, 1 sell. Over the last six months there have been 5 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GILD forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Gilead Sciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Dominant HIV franchise. Gilead leads the global HIV market with widely prescribed regimens like Biktarvy (about $3.8 billion of sales in the second quarter of 2026, up 7%) and long-acting prevention. The most optimistic published target, $180.00, assumes this works close to its best case.

The case against. Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. The most pessimistic target, $126.00, is roughly what GILD is worth if this bites instead.

Read the full bull and bear case on GILD, including what would have to change to break either one. Walnut is not an investment adviser.

No. Gilead Sciences, Inc. (GILD) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Gilead Sciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$30.5 billion
• Revenue growth (latest quarter, YoY): ~10%
• Operating margin: ~34%
• Net income (TTM): ~-$3.2 billion (acquired IPR&D charges)
• P/E (forward): ~16x (trailing not meaningful)
• Dividend yield: ~2.1% ($3.28 per share)
• Free cash flow (TTM): ~$9.8 billion
• Market cap: ~$194 billion

Gilead is valued as a mature, cash-generative biopharma at about 16 times forward earnings, above where it traded a year ago after a roughly 28% gain in 2026. Reported earnings are negative over the last twelve months because of about $11 billion of acquired research charges, so investors focus on product revenue (guided to $30.1-30.4 billion for 2026) and free cash flow. Third-quarter results are due October 29, 2026, with consensus near $2.20 of adjusted EPS on about $7.8 billion of revenue.

If you want GILD exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses GILD naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to GILD: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GILD exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (XLV, VHT, COWZ), which spreads the position across many companies. Or build it into a focused thematic portfolio, so GILD sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GILD fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Gilead Sciences (GILD) is an income-oriented biopharma anchored by a standard-of-care HIV business that funds research, acquisitions, and a dividend yielding about 2% at today's price. In a portfolio it behaves as a defensive healthcare holding with modest overall growth, where the payoff hinges on managing HIV patent cliffs, growing Yeztugo, and proving that the roughly $11 billion of oncology deals booked in the second quarter of 2026 earn their cost. The stock has rerated sharply in 2026 (up about 32% over one year), so expectations are higher than they were a year ago.

Whether GILD is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GILD a buy or a sell?, and where the stock could go from here in the GILD stock forecast.

For income investors, whether GILD pays a dividend and how the payout looks is covered in does GILD pay a dividend? And to weigh GILD against a peer, read the full side-by-side comparisons: GILD vs VRTX and GILD vs AMGN.